2-fluoropyrimidine
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Dec 31, 2019 (NCT04188145)
Timeline
Indications
Mechanism of action
- Thymidylate synthaseINHIBITOR
TYMS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-fluoropyrimidine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06648785 | Phase 2 | Oct 21, 2024 | University of Vermont |
| NCT05141721 | Phase 2/Phase 3 (Phase 3) | Feb 28, 2022 | Gritstone Oncology, Inc. |
| NCT04257461 | Phase 3 | Feb 15, 2020 | Belgian Group of Digestive Oncology, Cancer Research UK, Kom Op Tegen Kanker |
| NCT04188145 | Phase 3 | Dec 31, 2019 | University of Burgundy |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Belgian Group of Digestive Oncology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Gritstone Oncology, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Kom Op Tegen Kanker | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Burgundy | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Vermont | Academic/Hospital | 1 | 1 | 1 | 2024 |
6 organizations
Page 1 / 1